Overcome Uncertainty. Give Your Patients The Power to Know.
Provide clear answers instead of probable diagnoses. The SAAmplify-ɑSYN test detects misfolded ɑ-synuclein, correlates with autopsy findings, and gives you and your patients the biological insights needed for informed treatment decisions.
For me, the exciting part of Amprion and where we are together is that we are the next step in a technological breakthrough that allows us to see a whole family of diseases that couldn't be approached before.
4 Critical Reasons to Include ɑ-synuclein Testing in Your Practice
Clinical symptoms only reveal part of the story. Our test detects underlying ɑ-synuclein pathology that traditional assessment cannot identify, offering insight into mixed pathologies and allowing for early, accurate detection.
01
Detect Biology, Not Just Symptoms
Traditional diagnosis relies on clinical symptoms that appear only after significant neuronal damage has occurred. The SAAmplify-ɑSYN test detects the underlying pathology early and accurately, even for prodromal cases.
02
Autopsy-Confirmed Results
Synucleinopathies present with overlapping clinical phenotypes. The SAAmplify-ɑSYN test detects misfolded ɑ-synuclein, demonstrating over 98% correlation with diffuse Lewy body disease in autopsy cohorts.
03
Reveal Mixed Pathology Previously Hidden
Our proprietary seed amplification assay (SAA) technology shows near-perfect correlation with postmortem pathological findings, allowing you to detect with confidence what previously could only be confirmed at autopsy.
04
Identify Disease Early and Accurately
Research shows that up to 50% of clinically diagnosed Alzheimer's patients have ɑ-synuclein pathology at autopsy. The SAAmplify-ɑSYN test can identify misfolded ɑ-synuclein as early as MCI stage, enabling more precise clinical management.
Support Your Clinical Decision Making with Biology
Move from probable to informed diagnosis with biological data that impacts all aspects of patient care. From medication selection to progression planning, SAAmplify-ɑSYN results provide the objective evidence needed for confident, personalized treatment approaches.
Diagnostic Confidence
Detection of ɑ-synuclein pathology helps to distinguish between clinically similar conditions with different underlying causes.
Therapeutic Decision-Making
Knowing a patient’s biology, especially before symptoms of ɑ-synuclein mixed pathology appear, can allow you to minimize the risk of a patient receiving contraindicated medications and optimize management.
Prognostic Insights
Better anticipate disease course and progression by understanding the specific pathological processes at work, allowing for more effective care planning.
Clinical Applications
The SAAmplify-aSYN test provides valuable insights across the spectrum of neurodegenerative disorders.
For Cognitive Disorders
ɑ-synuclein pathology is present in Lewy body dementia and surprisingly common in Alzheimer's disease. The SAAmplify-ɑSYN test helps identify mixed pathologies that can significantly impact clinical management and prognosis.
For Movement Disorders
ɑ-synuclein pathology is the defining feature of Parkinson's disease and several atypical parkinsonian syndromes. The SAAmplify-ɑSYN test helps differentiate true synucleinopathies from other movement disorders with similar clinical presentations.
Unmatched Scientific Validation
Our technology isn't just innovative—it's extensively validated through rigorous scientific research and real-world clinical application. SAAmplify-aSYN is the only clinical test that has demonstrated autopsy confirmations. It has also been documented in peer-reviewed publications. This robust validation—including third-party studies with blinded samples and autopsy-confirmation—is empowering clinical decision-making, research advancement, and ultimately, patient care.
400
autopsy confirmations
1,200+
scientific publications
20,000
samples
Here’s How it Works
A simple three-step process that delivers clear biological answers.
Step 1
Once the test is ordered by a physician, CSF is collected via a routine lumbar puncture procedure. The CSF sample is sent to the Amprion lab.
Step 2
The SAAmplify assay detects the presence or absence of as few as 10 misfolded ɑ-synuclein molecules in the sample. Results are provided to the physician, who reviews them with the patient.
Step 3
Clear detected/not detected results help confirm or rule out ɑ-synuclein pathology, with results that correlate to autopsy findings with unprecedented accuracy.
Get in the Know
Bring biological certainty to your diagnosis with Amprion's SAAmplify-ɑSYN test. Order your shipping kits today and help move your patient beyond a probable diagnosis.
